HER2-positive breast cancer: From trastuzumab to innovatory anti-HER2 strategies

Clinical Breast Cancer

Volumn 8, Issue 1, 2008, Pages 38-49

  Whenham, Nicolas ^a   D'Hondt, Véronique ^a   Piccart, Martine J ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Farnesyltransferase inhibitors; Lapatinib; Signaling pathways; Targeted therapy; Vascular endothelial growth factor

Indexed keywords

4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; AP 23573; BIBW 2992; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIRUBICIN; ERTUMAXOMAB; EVEROLIMUS; FLUOROURACIL; LAPATINIB; LONAFARNIB; NAVELBINE; PACLITAXEL; PERTUZUMAB; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; TAMOXIFEN; TANESPIMYCIN; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANOREXIA; ASTHENIA; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CARDIOTOXICITY; CHILL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEPRESSION; DIARRHEA; DRUG DISTRIBUTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG PROTEIN BINDING; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; LEUKOPENIA; LIVER CYTOLYSIS; LYMPHOCYTOPENIA; MUCOSA INFLAMMATION; NAUSEA; NONHUMAN; PAIN; PRACTICE GUIDELINE; PROTEIN TARGETING; RASH; REVIEW; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; STOMATITIS; THROMBOCYTOPENIA;

EID: 40449135065     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2008.n.002     Document Type: Review

References (99)

1. AL Schechter DF Stern L Vaidyanathan The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen Nature 312 1984 513 516
2. Y Yarden MX Sliwkowski Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 2001 127 137
3. G Atalay F Cardoso A Awada Novel therapeutic strategies targeting the epidermal growth factor (EGFR) family and its downstream effectors in breast cancer Ann Oncol 14 2003 1346 1363
4. D Harari Y Yarden Molecular mechanisms underlying ErbB2/HER2 action in breast cancer Oncogene 19 2000 6102 6114
5. WG An RC Schnur L Neckers Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity Cancer Chemother Pharmacol 40 1997 60 64
6. DJ Slamon GM Clark SG Wong Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182
7. DJ Slamon W Godolphin LA Jones Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 1989 707 712
8. BA Gusterson RD Gelber A Goldhirsch Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group J Clin Oncol 10 1992 1049 1056
9. M Dowsett J Bartlett IO Ellis Correlation between immunohistochemestry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centers J Pathol 199 2003 418 423
10. AC Wolff ME Hammond DF Hayes American Society of Clinical Oncology/College of American pathologists guideline recommendations for Human Epidermal Growth Factor Receptor 2 testing in breast cancer J Clin Oncol 25 2007 118 145
11. J Mendelsohn J Baselga Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer J Clin Oncol 21 2003 2787 2799
12. R Nahta FJ Esteva HER-2 targeted therapy: lessons learned and future directions Clin Cancer Res 9 2003 5078 5084
13. RA Clynes TL Towers LG Presta Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets Nat Med 6 2000 443 446
14. J Baselga X Carbonell NJ Castañeda-Soto Phase II study of efficacy, safety and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule J Clin Oncol 23 2005 2162 2171
15. A Seidman C Hudis MK Pierri Cardiac dysfunction in the trastuzumab clinical trials experience J Clin Oncol 20 2002 1215 1221
16. TM Suter N Cook-Bruns C Barton Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer Breast 13 2004 173 183
17. CL Vogel MA Cobleigh D Tripathy Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 2002 719 726
18. MA Cobleigh CL Vogel D Tripathy Multinational study of the efficacy and safety of humanized anti-HER2 antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic breast disease J Clin Oncol 17 1999 2639 2648
19. FJ Esteva V Valero D Booser Phase II study of weekly docetaxel and trastuzumab for patients with HER2-overexpressing metastatic breast cancer J Clin Oncol 20 2002 1800 1808
20. G Fountzilas D Tsavdaridis A Kalogera-Fountzila Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperation Oncology Group phase II study Ann Oncol 12 2001 1545 1551
21. R Bell S Verma M Untch Maximizing clinical benefit with trastuzumab Semin Oncol 31 5 suppl 10 2004 35 44
22. HJ Burstein LN Harris PK Marcom Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm J Clin Oncol 21 2003 2889 2895
23. N Robert B Leyland-Jones L Asmar Randomized phase III study of trastuzumab, paclitaxel and carboplatin compared with trastuzumab and paclitaxel in women with HER2-overexpressing metastatic breast cancer J Clin Oncol 24 2006 2786 2792
24. S Chia M Clemons LA Martin Pegylated liposomal doxorubicin and trastuzumab in HER2 overexpressing metastatic breast cancer: a multicenter phase II trial J Clin Oncol 24 2006 2773 2778
25. N Bangemann A Kuhle A Ebert Capecitabine combinded with trastuzumab in therapy of intensively pretreated HER2-overexpressing metastatic breast cancer (MBC) Ann Oncol 11 suppl 4 2004 143a
26. EA Perez VS Suman KM Rowland Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252 Clin Breast Cancer 6 2005 425 432
27. M Pegram J Forbes T Pienkowski BCIRG 007: first overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first-line therapy in HER2 amplified metastatic breast cancer (MBC) J Clin Oncol 25 18 suppl 2007 34s (Abstract LBA1008).
28. DJ Slamon B Leyland-Jones S Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792
29. MJ Piccart-Gebhart Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: what we know and what we still need to learn Eur J Cancer 42 2006 1715 1719
30. MJ Piccart-Gebhart M Procter B Leyland-Jones Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 2005 1659 1672
31. EH Romond EA Perez J Bryant Trastuzumab plus adjuvant chemotherapy for operable HER-2 positive breast cancer N Engl J Med 353 2005 1673 1684
32. D Slamon W Eiermann N Robert Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophophamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study Breast Cancer Res Treat 94 suppl 1 2005 s5 (Abstract1).
33. H Joensuu PL Kellokumpu-Lehtinen P Bono Trastuzumab in combination with docetaxel or vinorelbine as adjuvant treatment of breast cancer: the FinHer trial Breast Cancer Res Treat 94 suppl 1 2005 s5 (Abstact 2).
34. TM Suter M Procter DJ van Veldhuisen Trastuzumab-associated cardiac side effects in the Herceptin Adjuvant (HERA) Trial J Clin Oncol 25 2007 3859 3865
35. Dinh P, de Azambuja E, Piccart-Gebhart MJ. Trastuzumab for early breast cancer: current status and the future direction. In Press.
36. J Baselga A new anti-ErbB2 strategy in the treatment of cancer: prevention of ligand dependent ErbB2 receptor heterodimerization Cancer Cell 2 2002 93 95
37. R Natha MC Hung FJ Esteva The HER2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells Cancer Res 64 2004 2343 2346
38. DB Agus MS Gordon C Taylor Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer J Clin Oncol 23 2005 2534 2543
39. J Cortes J Baselga P Kellokumpu-Lehtinen Open label, randomized, phase II study of pertuzumab (P) in patients (pts) with metastatic breast cancer (MBC) with low expression of HER2 J Clin Oncol 24 16 suppl 2005 208s (Abstract 3068).
40. J Baselga D Cameron D Miles Objective response rate in a phase II multicenter trial of pertuzumab, a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab in patients with HER2 positive metastatic breast cancer which has progressed during treatment with trastuzumab J Clin Oncol 25 18 suppl 2007 33s (Abstract 1004).
41. P Kiewe S Hasmuller M Untch Phase I trial of the trifunctional anti-HER2 and anti-CD3 antibody ertumaxomab in metastatic breast cancer Clin Cancer Res 12 2006 3085 3091
42. W Xia RJ Mullin BR Keith Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and Akt pathways Oncogene 21 2002 6255 6263
43. W Xia LH Liu P Ho Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016 Oncogene 23 2004 646 653
44. GE Konecny MD Pegram N Venkatesan Activity of the dual kinase inhibitor lapatinib (GW572016) against HER2-overexpressing and trastuzumab-treated breast cancer cells Cancer Res 66 2006 1630 1639
45. I Chu K Blackwell S Chen The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation-and estrogen-dependent gene expression in antiestrogen-resistant breast cancer Cancer Res 65 2005 18 25
46. R Nahta LX Yuan FJ Esteva Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insuline-like growth factor I signaling Mol Cancer Ther 6 2007 667 674
47. PA DeSimone AK Bence EB Anderson A phase I study to investigate the safety, tolerability, and pharmacokinetics of single oral escalating doses of GW572016 in healthy volunteers Proc Am Soc Clin Oncol 2002 21 (Abstract 375).
48. HA Burris HI Hurwitz EC Dees Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas J Clin Oncol 23 2005 5305 5313
49. EA Perez JA Byrne IW Hammond Results of an analysis of cardiac function in 2,812 patients treated with lapatinib J Clin Oncol 24 18 suppl 2006 23s (Abstract 583).
50. HL Gomez MA Chavez DC Doval A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a firstline treatment in patients with FISH positive advanced or metastatic breast cancer J Clin Oncol 23 16 suppl 2005 203s (Abstract 3046).
51. NL Spector K Blackwell J Hurley EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer: clinical activity and biologic predictors of response J Clin Oncol 24 18 suppl 2006 3s (Abstract 502).
52. NU Lin LA Carey MC Liu Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer J Clin Oncol 24 18 suppl 2006 3s (Abstract 503).
53. CE Geyer J Forster D Lindquist Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2006 2733 2743
54. B Moy PE Goss Lapatinib: current status and future directions in breast cancer Oncologist 11 2006 1047 1057
55. SK Rabindran CM Discafani A Wissner Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase Cancer Res 64 2004 3958 3965
56. A Reid S Vidal J de Bobo Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu) Eur J Cancer 43 2007 481 489
57. N Lewis J Marshall A Amelsberg A phase I escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor in a 3 week on 1 week off schedule in patients with advanced solid tumors J Clin Oncol 24 18 suppl 2006 143s (Abstract 3091).
58. P Traxler PR Allegrini R Brandt AEE788 : a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity Cancer Res 64 2004 4931 4941
59. E Martinelli CH Takimoto AT van Oosterom AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptors family tyrosine kinase: preliminary phase I results J Clin Oncol 23 16 suppl 2005 201s (Abstract 3039).
60. T Schmelzle MN Hall TOR, a central controller of cell growth Cell 103 2000 253 262
61. M Hidalgo EK Rowinsky The rapamycine-sensitive signal transduction pathway as a target for cancer therapy Oncogene 19 2000 6680 6686
62. MM Mita A Mita EK Rowinsky Mammalian target of rapamycin: a new molecular target for breast cancer Clin Breast Cancer 4 2003 126 137
63. K Yu L Toral-Barza C Discafani mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer Endoc Relat Cancer 8 2001 249 258
64. S Chan ME Scheulen S Johnson Final results of a phase II study of single-agent CCI-779 in locally advanced or metastatic breast cancer failing prior anthracycline and/or taxane regimens Breast Cancer Res Treat 82 suppl 1 2003 S82
65. S O'Donnel I Faivre C Judson A phase I study of the oral mTOR inhibitor RAD001 as monotherapy to identify the optimal biologically effective dose using toxicity, pharmacokinetic and pharmacodynamic endpoints in patients with solid tumors Proc Am Soc Clin Oncol 22 2003 200 (Abstract 803).
66. LW Chow Y Sun J Jassem Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer Breast Cancer Res Treat 100 suppl 1 2006 s286 (Abstract 6091).
67. A Migliaccio M Di Domenico G Castoria Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells EMBO J 15 1996 1292 1300
68. S Sebti A Hamilton Farnesyltransferase inhibitors and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench to bedside translational studies Oncogene 19 2000 6584 6593
69. R Daly M Binder RL Sutherland Overexpression of the Grb2 gene in human breast cancer cell lines Oncogene 9 1994 2723 2727
70. G Prendergast Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects Current Opin Cell Biol 12 2000 166 173
71. SR Johnston T Hickish P Ellis Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyltransferase inhibitor R115777 in advanced breast cancer J Clin Oncol 21 2003 2492 2499
72. JS de Bono G Schwartz L Hammond Concommitant HER2 and farnesyltransferase blockade by R115777 and trastuzumab in patients with advanced cancer Br J Cancer 86 suppl 1 2002 s110 (Abstract).
73. WG An RC Schnur L Neckers Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity Cancer Chemother Pharmacol 40 1997 60 64
74. B Zsebik A Citri J Isola Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1 Immunol Lett 104 2006 146 155
75. MA Read AS Neish FW Luscinskas The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression Immunity 2 1995 493 506
76. JC Cusack Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib Cancer Treat Rev 1 2003 21 31
77. EG Mimnaugh C Chavany L Neckers Polyubiquitination and proteosomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin J Biol Chem 271 1996 22796 22801
78. H Ichijo From receptor to stress-activated MAP kinases Oncogene 18 1999 6087 6093
79. F Phillips P Mullen BP Monia Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer Br J Cancer 85 2001 1753 1758
80. JF Lyons S Wilhelm B Hibner Discovery of a novel raf kinase inhibitor Endocr Relat Cancer 8 2001 219 225
81. I Vivanco CL Sawyers The phosphatidylinositol 3-kinase AKT pathway in human cancer Nat Rev Cancer 2 2002 489 501
82. G Valabrega F Montemurro M Aglietta Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer Ann Oncol 18 2007 977 984
83. P Nagy E Friedlander M Tanner Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC-4 expressing breast cancer cell line Cancer Res 65 2005 473 482
84. MA Molina R Sáez EE Ramsey NH(2)-terminal truncated HER2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer Clin Cancer Res 8 2002 347 353
85. Y Nagata KH Lan X Zhou PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Cancer Cell 6 2004 117 127
86. I Shin FM Yakes F Rojo PKB/Akt mediated cell-cycle progression by phosphorylation of p27 (Kip1) at threonine 157 and modulation of its cellular localization Nat Med 8 2002 1145 1152
87. R Nahta LX Yuan B Zhang Insuline-like growth factor-1 receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells Cancer Res 65 2005 11118 11128
88. G Valabrega F Montemurro I Sarotto TGFalpha expression impairs trastuzumab-induced HER2 downregulation Oncogene 24 2005 3002 3010
89. M Pegram S Hsu G Lewis Inhibitory effects of combinations of HER2/neu antibody and chemotherapeutic agents used for the treatment of human breast cancers Oncogene 18 1999 2241 2251
90. AD Seidman M Fornier F Esteva Final report: weekly herceptin and taxol for metastatic breast cancer: analysis of efficacy by HER2 immunophenotype (IHC) and gene amplification FISH Proc Am Soc Clin Oncol 19 2000 83a (Abstract 319).
91. M Marty F Cognetti D Maraninchi Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J Clin Oncol 2005 4265 4274
92. CK Osborne R Schiff Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer Breast 12 2003 362 367
93. MJ Ellis A Coop M Borgs Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or ErbB-2 positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial J Clin Oncol 19 2001 3808 3816
94. Wong ZW, Marcom K, Ellis MJ, et al. A phase II trial of the combination of letrozole and trastuzumab for ER and/or PgR and HER2 positive metastatic breast cancer. Presented at: the San Antonio Breast Cancer Symposium; December 4, 2003; San Antonio, Texas. Abstract 444.
95. JR Mackey B Kaufman M Clemens Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer Breast Cancer Res Treat 100 suppl 1 2006 s5 (Abstract 3).
96. AM Storniolo HA Buris B Overmoyer A phase I, open-label study of the safety, tolerability, and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab Breast Cancer Res Treat 94 suppl 1 2005 s64 (Abstract 1073).
97. B Linderholm K Grankvist N Wilking Correlation of vascular endothelial growth factor content with reccurences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment J Clin Oncol 18 2000 1423 1431
98. CN Baxevanis PA Sotiropoulou NN Sotiriadou Immunobiology of HER2/neu and its potential application in cancer immunotherapy Cancer Immunol Immunother 53 2004 166 175
99. S Limentani T Dorval S White Phase I dose-escalation trial of a recombinant HER2 vaccine with Stage II/III HER2+ breast cancer J Clin Oncol 23 18 suppl 2005 170s (Abstract 2520).